Awareness, Diagnosis, and Management of Osteoporosis in Adults with Developmental Disabilities

Similar documents
Clinician s Guide to Prevention and Treatment of Osteoporosis

Osteoporosis/Fracture Prevention

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS

1

Osteoporosis. Overview

Skeletal Manifestations

OSTEOPOROSIS: PREVENTION AND MANAGEMENT

Osteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis

Management of postmenopausal osteoporosis

Using the FRAX Tool. Osteoporosis Definition

The Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD

Fragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey

Guideline for the investigation and management of osteoporosis. for hospitals and General Practice

Disclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014

Osteoporosis: An Overview. Carolyn J. Crandall, MD, MS

NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT

Osteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital

Osteoporosis challenges

Current and Emerging Strategies for Osteoporosis

Learning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.

Forteo (teriparatide) Prior Authorization Program Summary

Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC

Osteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011

Objectives. Discuss bone health and the consequences of osteoporosis on patients medical and disability status.

Chapter 39: Exercise prescription in those with osteoporosis

New Developments in Osteoporosis: Screening, Prevention and Treatment

Osteoporosis Update. Greg Summers Consultant Rheumatologist

Osteoporosis Physician Performance Measurement Set. October 2006

Osteoporosis Clinical Guideline. Rheumatology January 2017

Osteoporosis. Treatment of a Silently Developing Disease

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK

Osteoporosis in Men Wendy Rosenthal PharmD. This program has been brought to you by PharmCon

Aromatase Inhibitors & Osteoporosis

Osteoporosis and Lupus. Andrew Ruthberg, MD University Rheumatologists

Osteoporosis: A Tale of 3 Task Forces!

John J. Wolf, DO Family Medicine

Dumfries and Galloway. Treatment Protocol for Osteoporosis

AACE/ACE Osteoporosis Treatment Decision Tool

Osteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.

Summary. Background. Diagnosis

This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against

Interpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm

Measuring Bone Mineral Density

What is Osteoporosis?

Overview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence

Osteoporosis: Who, What, When, Why, and How

Men and Osteoporosis So you think that it can t happen to you

My joints ache. What is the difference between osteoporosis and osteoarthritis?

Osteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK

OSTEOPOROSIS IN INDONESIA

Helpful information about bone health & osteoporosis Patient Resource

Breast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime

OSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO

PHC4 Issue Brief. Osteoporosis Facts and Figures. November 19, 1997

Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary

Dumfries and Galloway. Treatment Protocol for Osteoporosis

Assessment and Treatment of Osteoporosis Professor T.Masud

Nutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio

Page 1

Osteoporosis Physician Performance Measurement Set. October 2006 Coding Reviewed and Updated November 2009

An audit of osteoporotic patients in an Australian general practice

Updates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1

DXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi

Bone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008

ACP Colorado-Evidence Based Management of Osteoporosis

Horizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre

Download slides:

Treatment of Osteoporosis: IHFD 6 th March 2015

Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis

FRAX Based Lebanese Osteoporosis Guidelines Second Update for Lebanese Guidelines for Osteoporosis Assessment and Treatment

Horizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329

Use of DXA / Bone Density in the Care of Your Patients. Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist

Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017

Bone density scanning and osteoporosis

Understanding the Development of Osteoporosis and Preventing Fractures: WHO Do We Treat Now?

Bone Densitometry Pathway

BONE HEALTH Dr. Tia Lillie. Exercise, Physical Activity and Osteoporosis

BMD: A Continuum of Risk WHO Bone Density Criteria

Osteoporosis Update: Keys to Improving Diagnosis and Preventing Fractures

SpongeBone Menopants*

Learning Objectives. ! Students will become familiar with the 3 treatment solutions for osteoporosis. ! Students should be able to define osteoporosis

Introduction with terms of use agreement

Prevalence of Osteoporosis 5/3/2017. Rhiannon Anderson, PA-C, FLS Linda Mitchell, PA-C, FLS, DEXA Specialist

Clinical Practice. Presented by: Internist, Endocrinologist

BREAST CANCER AND BONE HEALTH

8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview

Because the low bone mass and deterioration

DISUSE OSTEOPOROSIS IN PATIENTS WITH POLIOMYELITIS

Building Bone Density-Research Issues

Prevalence of Osteoporosis p. 262 Consequences of Osteoporosis p. 263 Risk Factors for Osteoporosis p. 264 Attainment of Peak Bone Density p.

Long term Sequelae in Natural and Surgical Menopause

Pathway from Fracture or Risk Factor to Treatment

Update on Osteoporosis 2016

Osteoporosis and Bone Health. Heather Schickedanz, MD Geriatric Knowledge Network, 08/10/16

Submission to the National Institute for Clinical Excellence on

Osteoporosis Update. Case 2. Case 1: Monday morning, 8:15

Talking to patients with osteoporosis about initiating therapy

Page 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis

Osteoporosis. Osteoporosis ADD PICTURE

Osteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018

Transcription:

Awareness, Diagnosis, and Management of Osteoporosis in Adults with Developmental Disabilities Sunil J. Wimalawansa, MD, PhD, MBA, FACP, FRCP University Professor Professor of Medicine, Physiology & Pharmacology Endocrinology, Metabolism & Nutrition Director, Regional Osteoporosis Center UMDNJ-Robert Wood Johnson Medical School New Brunswick, NJ, USA

Health, Bones and Vitamin D Sunil Wimalawansa Professor of Medicine, Endocrinology & Nutrition IFCD.org - Caring for People with Disabilities

Why Osteoporosis is a Major Problem in DD Patients Men and women with developmental disabilities receive sub-standard health care (and perhaps, neglect) In particular, preventative services are under used in this population People with disabilities continue to face barriers to receiving health care (1 0 & 2 0 ) Access; Attitudes of providers Lack of information about health care needs

The Number of Americans with Chronic Conditions is Expected to Rise 33 Million in 2010 39 Million in 2020 28 Million in 1995

But Pool of Potential Caregivers are Shrinking

Economics of Care-Giving The value of services family caregivers provide for free is estimated to be over $290 billion/ yr twice as much as is actually spent on homecare and nursing home services. Of estimated 2.7 million Americans who need assistive technology such as wheelchairs, 64% can t afford it. In patients with DD, this is almost 100%

Incidence of Developmental Disabilities in US 26 million people with disabilities in US Many types of disabilities (ranging from mental health issues to multiple sclerosis) If a third has OP, this is an additional 8 million people with OP in USA alone (not accounted for) Over 500,000 people in US, over the age of 60 has developmental disabilities This number projected to be doubled by 2030

Time Line and Phases of Illnesses Patients with Chronic Disabilities, it is a Continuum, with a shorter life expectancy

Why Osteoporosis is a Major Problem in DD Patients The incidence of osteoporosis and fracture rates are over ten-times higher in developmental disabilities patients Diagnostic and the preventative services are grossly under used in this population They have multiple barriers to receiving health care (1 0 & 2 0 ) Access; Attitudes of providers Lack of information about health care needs

Osteoporosis & Disabilities: What is the Problem?

Loss of height Chest Abdomen Problems: Pain & difficulty Loss of independence Depression Loss of height Compression of chest & abdomen Treatment with inappropriate medications Increase morbidity and mortality

Identification of High-Risk Patients: Role of Age and Gender 5-Year Fracture Risk 20% Men 15% 10% Hip Vertebrae 5% Wrist Women Hip Vertebrae Wrist 35-39 >85 >85 Age Group, Year Cooper C, Melton LJ III. Trends Endocrinol Metab. 1992;3:224-229.

Osteoporotic (Fragility) Fractures Aging Propensity to fall High bone turnover Bone loss Fractures Low peak bone mass Menopause Developmental Abnormalities Hormonal environment Genetic factors Nutrition Exercise

Fracture Risk Doubles With Every S.D. Decrease in BMD 35 30 Relative Risk for Fracture 25 20 15 10 5 0-5.0-4.0-3.0-2.0-1.0 0.0 1.0 Bone Density (T-score)

History of Bone Density Testing New Jersey, 2007 100% 80% 60% 40% 20% 0% 50-59 60-69 70+ Women Men

What will be Discussed What is osteoporosis? Why should we worry about it? What are the issues facing with development disabilities? How can you make a diagnosis? What has been done for patients with disabilities? What can we do to improve the situation?

What is Osteoporosis?

Osteoporosis - Definition Skeletal disorder characterized by compromised bone strength, predisposing to increased risk of fractures * * National Institutes of Health Consensus Development Panel on Osteoporosis Prevention Diagnosis, and Therapy

According to the National Osteoporosis Foundation (NOF): 44 million people in the U.S. have low BMD (< 1g/cm 2 ) 11 million of those have osteoporosis 35 million have osteopenia and are at risk of for osteoporosis Projection: By 2020 there will be 15 million Americans with osteoporosis.

Trabecular Deterioration in Osteoporosis Normal Bone Osteoporosis

Osteoporosis is a Largely Under-diagnosed Condition Often diagnosed after a fracture Patient are usually asymptomatic prior to a fracture Low bone mineral density (BMD) is considered the disease Fragility fractures are the consequences of the disease

Osteoporosis affects the quality of bone

All Patients Receiving any of the Following Should be Advised of the Potential Risks of Osteoporosis Any chronic disability Gastrectomy / stapling GI pathology or surgery Any fragility fracture Glucocorticoid therapy Anti-convulsants Transplants / immuno-suppressant Depo-Provera, Lupron, etc.

Special Problems in Patients with Developmental Disabilities Intellectual (e.g., Down s syndrome) Other mental disabilities Physical & cognitive disability Immobility Excessive medication use ~40% taking anti-epileptics ~50% taking anti-psychotic medication Low vitamin D levels (high incidence)

Special Problems in Patients with Developmental Disabilities High incidence of non-traumatic fractures (8-18%) Low bone density (40-80%) Osteopenia (50%) & Osteoporosis (30%) Immobility & seizure disorders Medication use (anti-epileptics) Low vitamin D level ( sun exposure)

Condition Osteoporosis in Normal Persons vs. Patients with Developmental Disabilities Normal Population Developmental disabled patients Undiagnosed 40% 90% Prevalence of: Low bone density 15% 70% Vitamin D deficiency 40% 90% Falls 1 20-times higher Fracture rates 1 10-times higher Life expectancy 70-80 yrs 20-50 yrs

Some Facts About Osteoporosis: In older women, incidence of osteoporotic fractures is greater than incidence of myocardial infarction, stroke, and breast cancer combined. Can appear in both men and women; adults & children Osteoporosis and fractures are not solely the outcome of postmenopausal status in women

Importance of Risk Factors in the Diagnosis of Osteoporosis Risk factors are additive in predicting fractures

Combining BMD With Clinical Risk Factors Hip Fx Rate (per 1000 woman-years) 30 25 20 15 10 5 0 Lowest Third Heel BMD Middle Third Highest Third 0-2 3-4 5 # Risk Factors Cummings et al. N Engl J Med. 1995;332:767-773.

U.S. Fracture Incidence: Approx. 1.5 million people per year have osteoporosisrelated fragility fractures: 700,000 spine 300,000 hip 250,000 wrist 300,000 other Economic costs, including rehab, hospitalization, and nursing home care: Direct cost in 1995 - $13.8 billion 2003 -$17 billion 2008 -$21 billion www.nof.org

Health Costs of Osteoporosis- Related Falls and Fractures 1.5 million osteoporosis-related fractures in the U.S. annually In New Jersey osteoporosis-caused bone fractures (~36,630 each year), cost $496 million annually Hospitalization due to Hip fractures cost between $18,000-$26,912. Double by 2020 to an estimated $60,000. Falls the second leading cause of injury-related New Jerseyans 65 years and older >90 percent of hip fractures are associated with osteoporosis and nine out of 10 are the result of a fall. Between 2000 and 2005, fatality from falls among New Jerseyans 65 to 84 years old and 85 years and older has nearly doubled.

Low Bone Mass of Osteoporosis Have Multiple Causes Vitamin D deficiency Endocrine disorders: Glucocorticoid therapy, Cushing s disease Hyperparathyroidism Hyperthyroidism Drug toxicity (anti-epileptic drugs) Immobility Hypogonadism (in men and women)

Populations at Risk of Developing Osteoporosis & Fractures Glucocorticoid (steroid ) use Eating disorders Persistent amenorrhea Low sex-hormone levels Thyroid/parathyroid diseases Frequent fallers Developmental disabilities

70-Year-old Woman with Newly Diagnosed Temporal Arteritis, Treated with Prednisone A preventable cause of OP Baseline One Year Later

Common site of Fractures in developmentally disabled individuals Not different from normal population Cause is often undeterminable May lead to additional disabilities and premature death

Hip Fracture Complications 30% excess mortality within the year from the fracture (nearly 65,000 women die) 50% survivors are incapacitated 22% require long-term nursing home care Failure to diagnose and treat osteoporosis In 50% of the survivors, the second hip fracture occurs within four years ( Kamel HK,et al.am J Med 2000; 109:326-328). 328).

Diagnosis of Osteoporosis Begins with a DXA scan, which is normally straightforward in the general population Adults with DD may present with contractures, deformities, and movement disorders that may confound analysis of BMD. Regions of Interest (ROI s) may need to be adjusted for valid interpretation.

Bone Densitometry by Central DXA Bone density is the single best predictor of bone strength and fracture risk DXA is a major breakthrough in diagnosis and treatment of osteoporosis: Diagnose osteoporosis prior to fractures Assess an individual s risk for fracture Monitor therapy Hologic Norland GE Lunar

Example of a DXA Bone Density Testing Machine

DXA Measurements of Spine & Hip Lumbar spine Proximal femur Femoral neck Total hip Bone density diagnosis is based on result at lumbar spine, total hip, and femoral neck sites only Other sites (Ward s triangle, etc.) are not valid predictors of fracture risk

Treatment of Osteoporosis May require additional consideration of multiple co-morbid conditions No studies have been done to demonstrate efficacy of bone-building pharmaceuticals in persons with DD with low bone density Few medical specialists in treating metabolic bone disorders that are experienced with the health problems in DD population

Treatment of Osteoporosis There are no established standards of care for the evaluation and management of osteoporosis or fractures in DD population. More clinical data, research, and guidance are needed. IFCD Foundation is promoting such.

BMD Data Analysis of BMD from individuals who had baseline and follow-up DXA scans suggests: Calcium and Vitamin D alone are not sufficient to improve BMD Low BMD is more prevalent in the hips than in the spine Bisphosphonates appear to be more effective for low BMD of the spine, but very little effect on the hips Vitamin D treatment is highly costeffective

Treatment of Osteoporosis Even though it may increase the BMD, it is possible that none of the available FDAapproved anti-osteoporosis therapies will prevent fractures significantly in this community. In addition to low BMD, fractures in DD patients are due to a different set of reason than the normal population: Excessive use of drugs and drug interactions Poor balance, coordination and falls Aggression, etc.

Guidelines for BMD Measurements Most disabled patients aught to have BMD testing Should have baseline BMD prior to, or early as possible of starting therapy Follow-up annually until bone mass stabilizes, and then every 2-3 years Measuring one site alone may miss rapid loss of BMD in other site (spine vs. hip)

Very Little Research has been done in Patients with Development Disabilities

Osteoporosis Research in Patients with Developmental Disabilities Tyler et. al., Mental retardation, 38: 316-321, 2001 Wagemeans, A.M.A., et al, Am. J. Mental Retardation, 108: 340-346, 2002 Schrager, S., J. Intellectual Disability Research, 42: 370-374, 2003 Schrager, S., J Women s Health, 13: 431-437, 2004 Schrager S., Mental retardation, 44: 203-211, 2004 Milberger S., J. Intellectual Disability Research, 27: 273-280, 2002

Special Problems: Other Considerations As people age, their BMD decrease, while their risk of falls increase Many people with disabilities take medications that may predispose to falls e.g., agent with anti-cholinergic sideeffects, as prescribed for incontinence, drooling, neuropathy, allergies, or psychiatric drugs

Special Problems: Anti-convulsant Medications Impair vitamin D metabolism Phenytoin, Cabamezapine, Valproic acid Toxicity to osteoblasts: Phenytoin, Cabamezapine, Newer anti-epileptic agents ( Vt. D) Topiramide, Gabapentin, Lamotrigine, Ethosuximide Poor nutrition

Special Problems: e.g., Down s syndrome Lower peak bone mass Low bone density (up to 87%) Lower muscle tone Low vitamin D levels Increase falls and injuries Anti-convulsion medications Lives longer now High incidence of fractures

Special Problems: Spinal Cord Injuries & Stroke Immobility and lack of gravity may induce rapid bon loss in lower extremities (50% loss in 4 years) High incidence of fractures Lower muscle tone & low serum vitamin D levels Increase falls and injuries

Special Problems: Multiple Sclerosis and MG 350,000 people are affected with MS 75% of them are women Lower BMD, and High prevalence of vitamin D deficiency Poor muscle tone Increase falls and injuries High fractures rates

Special Considerations: Therapeutic Options Inability to take appropriate oral therapy e.g., oral bisphosphonates Annual or 3-monthly intravenous treatment with bisphosphonates Drug interactions (e.g., anti-convulsant) Immobility difficulties with exercise Loss of mechanical stresses Frequent use of glucocorticoids (e.g., in MS, myasthenia gravis)

Fall and Injury Prevention Institutionalized and bed-bound patients are at much higher risk of osteoporosis and associated fractures Many of these patients eventually develop pathological fractures with minor or no trauma Unfortunately, many law suites have been filed inappropriately (i.e., handling of these patients vs. OP as a cause of the fracture)

Fall and Injury Prevention (Very Important) Increase muscle strength Environmental modification Hip protective pads Attention to vision & hearing Avoid medications that affect balance and co-ordination

Discussion We do not know whether boneactive pharmaceutical agents are effective in the DD individuals. Early diagnosis, correcting vitamin D deficiency, and fall prevention are the most costeffective ways to address this disease in patients with developmentally disabilities.

Prevention of Fractures Each Patient is Unique Diagnosis-DXA: Documentation of osteoporosis or low bone mass Blood tests: Biochemical tests to exclude secondary causes of bone loss Special care: Education staff on how to handle these patients Therapy: Initiation of appropriate therapy such as vitamin D

Principals of Management of Osteoporosis What Can We Do? Identification and treatment of secondary causes of osteoporosis Ensure adequate calcium and vitamin D, and weight-bearing exercise Commencing and maintenance of an cost-effective therapy Follow-up and monitoring of patients

Prevention/Treatment of Osteoporosis: General Recommendations Calcium: ~1,500 mg/day from the diet and supplements Vitamin D ~ 2,000 to 4,000 IU/day (or 50,000 IU, twice a month) Weight-bearing exercise Avoidance of tobacco, & alcohol intake Minimize medications that adversely affecting skeleton Fall prevention program

Treatment Goal for Osteoporosis Fracture Reduction Improving bone density and maintaining the structural integrity is important and Falls and injury prevention is critical in preventing fractures

Agents used in the Prevention and Treatment of Osteoporosis (FDA Approved therapies) Adequate Calcium (~1,500 mg/day) and Vitamin D (~1,000 IU/day) intake Estrogen (± Progesterone) Bisphosphonates (Alendronate, Risedronate, Ibandronate, zoledronic acid) Calcitonin (a week agent) Selective estrogen receptor modulating agents (SERMs) (Raloxifene) PTH (1-34) - Teriparatide

Punch Line Osteoporosis: Bone loss and fractures are preventable, and Irrespective of the degree of bone loss, condition or the age, Osteoporosis is treatable

In the future, health care professionals taking care of disable patients will also need to be magicians, so that they will be able to check multiple things including bones without x-rays!

Summary Prevention is better than cure Identifying and eliminating secondary causes of bone losses Drug treatment may not be the answer Think Nutrition, Calcium, Vitamin D Weight-bearing exercises Eliminate risk factors Prevent falls & injuries

Summary 1. Prevention is better than cure 2. Adolescence - window of opportunity 3. Nutrition 4. Calcium/Vitamin D 5. Exercise 6. Eliminate risk factors 7. HRT/Bisphosphonates/SERMS 8. Prevent Falls

Discussion Other developmental centers Should consider having a Healthy Bones Initiative program at their facilities. With adequate identification, research, intervention, and data collection at the state-wide level, perhaps this could become a health topic in the national arena.

Don t forget to talk to your Patient and their family members about his/her Risks of Osteoporotic Fractures Fracture: Is osteoporosis Can be prevented Leads to more fractures

Vertebral Fractures: Accumulation of Cascade Fracture Fractures are preventable

Whoever we are, wherever we live, we are human beings